article · Antibiotics
Background/Objectives: Pseudomonas aeruginosa causes chronic infections in humans and animals, especially cats and dogs. This bacterium’s ability to adapt and acquire antibiotic resistance traits may complicate and exacerbate antibacterial therapy. This study aimed to evaluate the antibiotic resistance patterns, virulence factors and ability to form biofilms of P. aeruginosa strains isolated from Algerian dogs and cats. Methods: Nineteen samples were collected from healthy and diseased dogs and cats. Isolates were studied for their antibiotic-resistance patterns (disc diffusion method) and biofilm formation (Microtiter assay) and were whole-genome sequenced (MinION). Results: Nineteen P. aeruginosa strains (15 from dogs and 4 from cats) were isolated. Antibiotic-resistance phenotypes were observed against amoxicillin–clavulanic acid (100%); meanwhile, resistance towards ticarcillin was 40% (dogs) and 25% (cats), ticarcillin–clavulanic acid was 13.33% and 25% for dogs and cats, respectively, and imipenem was 75% (cats) and 20% (dogs). Moreover, 95% of strains were biofilm-producers. Different antimicrobial resistance genes (ARGs) were found: beta-lactamase genes, mainly PAO, OXA-494, OXA-50 and OXA-396 and an aminoglycoside gene (aph(3′)-IIb). The main high-risk sequence types (STs) were ST244, 2788, 388 and 1247. A large panel of virulence genes was detected: exoS, exoT, exoY, lasA, toxA, prpL, algD, rhIA and others. Conclusions: The genetic variety in antibiotic-resistance genes of resistant and virulent P. aeruginosa strains in dogs makes public health protection difficult. Continuous monitoring and research in compliance with the One Health policy are needed to solve this problem.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/antibiotics14030230
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.